$ZLAB is an interesting biotech stock, with a couple potentially explosive catalysts during 2023. There's a nice weekly signal here indicating the stock is accumulated and ready to move up strongly over time.
Remember to size these names considering the extreme volatility that can occur after drug trial data comes out, or if they receive an FDA approval, etc.
Best...
$ZLAB is a Chinese biotech company specializing in the treatment of cancer, among other things. In December an insider bought 4,000 shares. Also, hedge funds have been increasing their exposure to $ZLAB for the last 4 quarters. The stop is 7% below at the red line. There are 2 upper trend lines (yellow). My feeling is that $ZLAB will be unsuccessful at getting...
Zai Lab has partnered with Five Prime Therapuetics in the making and testing of the cancer treatment drug FPA144 + chemo (FIGHT). The stock is projected to rise 20+% on Friday, January 15, when the data is released. The data will be released 10:00-11:15 EST. Like and Follow if you want to see more trades like this.
ZLAB,MGNX: Zai Lab Limited
2020-12-16 20:15:08
Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
ZLAB: Zai Lab Limited
2020-05-28 07:37:40
Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer
After hit the pivot resistance, $ZLAB is pulling back to the support zone. It will most likely form a handle. If it breaks out $63.95, the pattern will be confirmed.
Secondary offering of 7.5 million shares at $20 per share.
Sell $20.00ish
I think the overreaction is due to investors starting to tighten up the belt due to market conditions.
Again, this is just a quick swing off this full retracement. This just seems a bit overly reactionary to me.
Stop 10%
